Latest News

Alexion submits application to Japan’s MHLW to extend Soliris indication to treat gMG

Alexion Pharmaceuticals has submitted an application to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalised myasthenia gravis...

Alexion submits application to Japan’s MHLW to extend Soliris indication to treat gMG

Cancer Research UK to support Precision Panc project for pancreatic cancer

Cancer Research UK to support Precision Panc project for pancreatic cancer

Argenx and Broteio Pharma partner to develop antibody for autoimmune diseases

Netherlands-based biotechnology company argenx and Broteio Pharma, a joint venture between Prothix and Bioceros, have agreed to partner for the development of a therapeutic antibody for...

Argenx and Broteio Pharma partner to develop antibody for autoimmune diseases

US FDA grants Fast Track designation for Shire’s SHP655

The US Food and Drug Administration (FDA) has granted Fast Track designation for Shire’s recombinant ADAMTS13 (SHP655 or previously known as BAX930) to treat acute episodes of hereditary...

US FDA grants Fast Track designation for Shire’s SHP655

British Columbia to provide public access to Gilead Sciences’ Epclusa for genotype 1-6 HCV

British Columbia to provide public access to Gilead Sciences’ Epclusa for genotype 1-6 HCV

Ferrier Research Institute and BCFNZ to create new breast cancer vaccine

Victoria University of Wellington's Ferrier Research Institute and the Breast Cancer Foundation New Zealand (BCFNZ) have joined forces to create a new vaccine for breast cancer....

Ferrier Research Institute and BCFNZ to create new breast cancer vaccine

US FDA approves Xadago to treat patients with Parkinson’s disease

US FDA approves Xadago to treat patients with Parkinson’s disease

CannRx and iCAN:Israel-Cannabis form JV to launch sleep cannabis formulation

CannRx Technologies and iCAN:Israel-Cannabis have announced the formation of a joint venture (JV) in a bid to market ican.sleep, the sleep cannabis formulation....

CannRx and iCAN:Israel-Cannabis form JV to launch sleep cannabis formulation

Swansea University scientists participate in study into genetics of common epilepsy

Academics from Swansea University have participated in a study designed to assess the contribution of genome-wide, ultra-rare genetic variation in common...

Swansea University scientists participate in study into genetics of common epilepsy

University of Sheffield and Parkinson’s UK launch new virtual biotech company

The University of Sheffield and research and support charity Parkinson’s UK have launched a new virtual biotech company to develop new treatments for people with...

University of Sheffield and Parkinson’s UK launch new virtual biotech company

US FDA approves Xermelo with SSA therapy to treat carcinoid syndrome diarrhoea

The US Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals’ Xermelo (telotristat ethyl) tablets in combination with somatostatin analog (SSA) therapy to treat adults...

US FDA approves Xermelo with SSA therapy to treat carcinoid syndrome diarrhoea

US FDA accepts priority review for EMD Serono's application for avelumab

The US Food and Drug Administration (FDA) has accepted priority review for EMD Serono's biologics licence application (BLA) for avelumab to treat patients with locally advanced or...

US FDA accepts priority review for EMD Serono's application for avelumab

Researchers initiate new non-invasive urinary test to fast-track drugs for Motor Neuron Disease

Researchers initiate new non-invasive urinary test to fast-track drugs for Motor Neuron Disease

Santen and twoXAR to identify new drug candidates for glaucoma

US-based ophthalmology company Santen and biopharmaceutical company twoXAR have entered a strategic research collaboration to identify new drug candidates for...

Santen and twoXAR to identify new drug candidates for glaucoma

Novartis and NHS Ayrshire & Arran launch new eye care facility in Scotland

Novartis Pharmaceuticals UK and NHS Ayrshire & Arran have announced the launch of a new facility designed specifically for people suffering from some of the most common forms of avoidable sight loss....

Novartis and NHS Ayrshire & Arran launch new eye care facility in Scotland

US researchers find vitamin B3 prevents glaucoma

US researchers find vitamin B3 prevents glaucoma

Is digital disruption of heart disease markets on the horizon?

Is digital disruption of heart disease markets on the horizon?

Cutting costs but not quality: heart failure hospitalisations

Cutting costs but not quality: heart failure hospitalisations

US FDA approves Siliq to treat plaque psoriasis

US FDA approves Siliq to treat plaque psoriasis

Eli Lilly and Incyte receive EC’s marketing authorisation approval for Olumiant

Eli Lilly and Incyte receive EC’s marketing authorisation approval for Olumiant

Vifor Pharma gains commercialisation rights for ChemoCentryx’s Avacopan in Asia

Swiss-based Vifor Pharma, a Galenica Group company, has gained commercialisation rights for ChemoCentryx’s Avacopan (CCX168) for orphan and rare renal diseases in Asia, including Japan and...

Vifor Pharma gains commercialisation rights for ChemoCentryx’s Avacopan in Asia